Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01940198

Acronym

REfLecT

Enrollment

117

Registered

2013-09-12

Start date

2010-04-30

Completion date

2012-09-30

Last updated

2013-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

Atazanavir, long-term, primary care setting, sydney

Brief summary

This observational study will aim to determine long-term atazanavir experience in a high HIV caseload primary care practice in Sydney, Australia.

Detailed description

This observational study will aim to determine long term atazanavir experience in HIV-1 infected patients in a primary care setting. 3\. OBJECTIVES OF THE STUDY i. Primary objective Long-term (2 years or greater) atazanavir experience in HIV-1 infected patients in a primary care setting through retrospective data collection. ii. Secondary objectives 1. To illustrate long term therapeutic efficacy of atazanavir in ART naïve and experienced HIV-1 infected patients. 2. To illustrate long term tolerability to atazanavir in ART naïve and experienced HIV-1 infected patients. 3. To identify ART treatment history in ART naïve and experienced HIV-1 infected patients on ATV. 4. To identify contraindicated therapy in ART naïve and experienced HIV-1 infected patients on ATV.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. HIV-1 positive 2. Have commenced ATV between 2002-2008 (Baseline) 3. Follow-up data (clinical and laboratory) available from baseline

Exclusion criteria

1. Patients not commenced ATV between 2002-2008 2. No follow-up data (clinical and laboratory) available from baseline 3. Patient 'lost to follow-up' with \< 2 years of follow-up data (Clinical and laboratory)

Design outcomes

Primary

Measure	Time frame	Description
Proportion of HIV-1 infected participants with atazanavir experience	1 year	Proportion of patients who continue on atazanavir for 2 years or greater from baseline to termination/current.

Secondary

Measure	Time frame	Description
Proportion of HIV-1 infected participants with atazanavir experience	1 year	1\. Therapeutic efficacy of atazanavir

Countries

Australia

Outcome results